BeiGene, Ltd. Overview
Pro stress-test →BeiGene is a global oncology company focused on discovering, developing, and commercializing cancer medicines, working to make treatments more affordable and accessible worldwide. The company operates across multiple exchanges (NASDAQ, HKEX, SSE) and has built a broad portfolio of novel therapeutics through internal research and external collaborations. BeiGene is repositioning itself as a global leader in innovative cancer treatments under a planned rebranding to BeOne Medicines.
Strategic Profile
Pro stress-test →BRUKINSA, the company's flagship BTK inhibitor, has become the market-leading product globally and in the U.S., with 2025 revenues of $3.9 billion (up 49% YoY). BeiGene delivered strong Q4 2025 results with product revenue of $1.5 billion in Q4 (up 32% YoY) and achieved GAAP profitability and significant free cash flow, marking an inflection point to scale and sustained earnings. For 2026, the company is guiding for revenue between $6.2 billion and $6.4 billion, with gross margins expected in the high 80% range and GAAP operating income of $700–800 million.
Competitive Landscape
Pro stress-test →Key competitors in the oncology space include Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma. BeiGene's BRUKINSA has achieved market leadership among BTK inhibitors with widening competitive advantage based on superior long-term clinical outcomes.
Industry Context
BeiGene, Ltd. operates in Biopharmaceuticals / Oncology.
Key facts
Founded: 2010 · Headquarters: Beijing, China · Employees: ~2,295 · Revenue: $6.2B–$6.4B (2026E) · Market cap: $19.7B